Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
Clinical trial NCT06683755 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06683755
- Sponsor
- M.D. Anderson Cancer Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-01
- Primary completion
- 2030-08-16
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.